Article
Immunology
Korbinian N. Kropp, Martina Fatho, Enes Huduti, Marilena Faust, Silke Luebcke, Volker Lennerz, Annette Paschen, Matthias Theobald, Thomas Woelfel, Catherine Woelfel
Summary: This study isolated two CSPG4-reactive T-cell clones and confirmed their specific and efficient recognition of CSPG4+HLA-C*07:01+ cancer cells. Cross-over TCR constructs also showed some level of activity, suggesting potential for further preclinical and clinical evaluation.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Azadehsadat Razavi, Mahsa Keshavarz-Fathi, John Pawelek, Nima Rezaei
Summary: CAR T cell therapy has emerged as a promising cancer treatment, showing initial success in hematologic malignancies and progress in solid tumors like melanoma. Targeting specific tumor antigens like CSPG4, CD70, and GD2 has been a focus in CAR-T cell therapy for melanoma, although challenges remain.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
(2021)
Article
Immunology
Pornpimon Yuti, Yupanun Wutti-in, Nunghathai Sawasdee, Katesara Kongkhla, Nattaporn Phanthaphol, Kornkan Choomee, Thaweesak Chieochansin, Aussara Panya, Mutita Junking, Pa-thai Yenchitsomanus, Jatuporn Sujjitjoon
Summary: Adoptive T cell therapy using second-generation anti-CD19 chimeric antigen receptor T cells has shown promising results in the treatment of B-ALL and DLBCL. However, the efficacy in aggressive B cell lymphomas is limited due to poor T cell function caused by the interaction between PD-L1 on BCL cells and PD-1 receptor on T cells. To overcome this, researchers have generated anti-CD19-CAR5-T cells that secrete anti-PD-L1 scFv, which has shown improved antitumor efficiency against CD19+/PD-L1high tumors.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Nanoscience & Nanotechnology
Xuandong Lin, Haixia Li, Xi Li, Xiaomei Yang, Wei Shi, Ziqiang Ding, Dani Zhong, Yangzi Li, Wenli Yang, Xia Yu, Shenxia Xie, Xiaobing Jiang, Xiaoling Lu
Summary: The novel antibody-chemokine fusion protein hENG scFv/hIP-10 demonstrated enhanced anti-tumor activity of cytokine-induced killer cells against human hepatocellular carcinoma, leading to inhibited tumor growth and prolonged survival in a mouse model.
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Maryam Bahmanyar, Mohammad Kazem Vakil, Ghaidaa Raheem Lateef Al-Awsi, Seyed Amin Kouhpayeh, Hosein Mansoori, Yaser Mansoori, Afsaneh Salahi, Ghasem Nikfar, Alireza Tavassoli, Esmaeil Behmard, Ali Moravej, Abdolmajid Ghasemian
Summary: CAR-T cell therapy and adoptive cell therapy have shown efficacy in the treatment of melanoma, but there are still drawbacks, such as rare tissue infiltration, off-target toxicity, and resistance development in CAR-T cell based therapy. Future studies should focus on selecting suitable target antigens and novel engineered immune cells to improve treatment outcomes.
MOLECULAR BIOLOGY REPORTS
(2022)
Article
Oncology
Neelakshi Mungra, Fleury A. N. Biteghe, Zaria Malindi, Allan M. M. Huysamen, Maryam Karaan, Natasha S. S. Hardcastle, Rubina Bunjun, Shivan Chetty, Krupa Naran, Dirk Lang, Wolfgang Richter, Roger Hunter, Stefan Barth
Summary: This study engineered a CSPG4-targeting ADC using SNAP-tag technology, which demonstrated selective delivery of drugs to TNBC cells through in vitro experiments, and showed its cell-killing ability on target cells.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Laura Gehrcken, Tatjana Sauerer, Niels Schaft, Jan Doerrie
Summary: Merkel cell carcinoma is a rare and aggressive skin cancer, predominantly caused by Merkel cell polyomavirus or UV light. Checkpoint inhibitor therapies like PD-1/PD-L1 inhibitors show promise in treating metastatic MCC, but some patients do not respond due to diverse immune-related adverse events caused by various mechanisms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Stefanie Hoyer, Valentina Eberlein, Gerold Schuler, Carola Berking, Lucie Heinzerling, Niels Schaft, Jan Doerrie
Summary: This study investigated the impact of BRAFi/MEKi on the maturation of monocyte-derived dendritic cells (moDCs) and their interaction with T cells. The findings showed that these inhibitors altered cytokine secretion and surface marker expression of DCs, leading to lower activation markers and cytokine secretion in T cells during antigen-specific stimulation。
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biotechnology & Applied Microbiology
Andreas Hombach, Markus Barden, Lisa Hannappel, Markus Chmielewski, Gunter Rappl, Agapios Sachinidis, Hinrich Abken
Summary: This study presents a new prototype of CARs that improves tumor recognition and elimination by incorporating the cytokine IL12 into the CAR exodomain. It reprograms CAR T cells to have NK cell-like functional capacities, allowing them to target and eliminate antigen-negative cancer cells.
Article
Virology
Astrid Strack, Andrea Deinzer, Christian Thirion, Silke Schroedel, Jan Doerrie, Tatjana Sauerer, Alexander Steinkasserer, Ilka Knippertz
Summary: In this study, the use of LentiBOOST(R)/Polybrene significantly improved the transduction rate of HAdV-5 in various immune cells in both mice and humans, without affecting their phenotype and function.
Article
Immunology
Elias A. T. Koch, Niels Schaft, Mirko Kummer, Carola Berking, Gerold Schuler, Kenichiro Hasumi, Jan Doerrie, Beatrice Schuler-Thurner
Summary: Uveal melanoma is a rare disease with poor response to traditional therapies. Researchers designed a trial using personalized dendritic cell vaccines to activate the immune system and potentially improve clinical outcomes.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell Biology
Xin Lai, Christine Keller, Guido Santos, Niels Schaft, Jan Doerrie, Julio Vera
Summary: Dendritic cells (DCs) can be used for therapeutic vaccination against cancer. Computational modeling can improve our understanding of the molecular mechanisms underlying DC-induced CTL response and help identify new strategies to improve therapeutic DC vaccination for cancer.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Amke C. Beenen, Tatjana Sauerer, Niels Schaft, Jan Doerrie
Summary: PD-L1 is a transmembrane protein that plays a crucial role in immune modulation. It interacts with its receptor PD-1 to induce an immune-suppressive signal, regulating the activity of T cells and other effector cells. Apart from its application in cancer therapy, the role of PD-L1 in healthy tissue and non-cancerous diseases has been largely overlooked.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Dennis Christoph Harrer, Charlotte Schenkel, Carola Berking, Wolfgang Herr, Hinrich Abken, Jan Doerrie, Niels Schaft
Summary: In this study, the FDA-approved drug decitabine was used to upregulate the expression of CSPG4 in ovarian carcinoma cells, expanding the repertoire of targetable antigens. The results demonstrated the potential of CSPG4 as an inducible antigen for CAR-T cells in ovarian cancer.
Article
Multidisciplinary Sciences
Lukas Heger, Lukas Hatscher, Chunguang Liang, Christian H. K. Lehmann, Lukas Amon, Jennifer J. Luehr, Tomasz Kaszubowski, Rayk Nzirorera, Niels Schaft, Jan Doerrie, Pascal Irrgang, Matthias Tenbusch, Meik Kunz, Eileen Socher, Stella E. Autenrieth, Ariawan Purbojo, Horia Sirbu, Arndt Hartmann, Christoph Alexiou, Robert Cesnjevar, Diana Dudziak
Summary: Dendritic cells (DCs) are important regulators of immune responses, and can be classified into different types. One type of human DCs, called cDC1, can be distinguished based on the expression of XCR1. XCR1(+) cDC1 have a pre-activated phenotype, secrete high levels of inflammatory cytokines and chemokines upon stimulation, and are efficient in activating NK cells as well as inhibiting replication of Influenza A virus. XCR1(-) cDC1, on the other hand, may represent a late immediate precursor of cDC1 and secrete comparable level of inflammatory cytokines after differentiation.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Article
Immunology
Felix Pfister, Jan Doerrie, Niels Schaft, Vera Buchele, Harald Unterweger, Lucas R. Carnell, Patrick Schreier, Rene Stein, Marketa Kubankova, Jochen Guck, Holger Hackstein, Christoph Alexiou, Christina Janko
Summary: The influence of superparamagnetic iron oxide nanoparticles (SPIONs) on primary human T cells and their potential for magnetically targeted adoptive T cell therapy were investigated in this study. Results showed that SPION-loading did not affect the mechanics and functionality of T cells, indicating its potential for magnetically enriching T cells in solid tumors.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Dennis Christoph Harrer, Jan Doerrie, Niels Schaft
Summary: The development of CAR-T cells has revolutionized cancer immunotherapy, but there are challenges such as relapse or refractory disease in some patients, especially those with solid tumors. Obstacles to successful CAR-T cell therapy include antigen shutdown and CAR-T cell dysfunctionality. This review highlights different approaches, including combining CAR-T cells with drugs, to overcome these obstacles and improve the efficacy of CAR-T cell therapy in both hematological malignancies and solid tumors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)